ArticleUpdates in surgery2026
Therapeutic potential of epidermal growth factor for perianal fistulas: an experimental rat model.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the effects of Epidermal Growth Factor (EGF) on wound healing, inflammation, and apoptosis markers in a rat perianal fistula model and to compare these effects with conventional seton placement, Tarantula cubensis venom (Theranekron® D6), or a combination (S + T). We hypothesized that EGF could enhance epithelial and granulation tissue repair while limiting local inflammatory damage. A total of 28 male Wistar rats were randomly allocated to four groups (n = 7 each). Perianal fistulas were experimentally induced, and interventions were administered as follows: Group S (loose seton only), Group T (Tarantula venom subcutaneously, weekly), Group S + T (seton plus tarantula venom), and EGF (two doses of 15 µg EGF near the fistula tract). After a 30-day follow-up, the animals were euthanized and the perianal regions were excised. Re-epithelialization, granulation tissue, inflammatory cell infiltration, and Caspase-3 immunostaining were analyzed. Data were statistically assessed using Kruskal-Wallis and post-hoc tests (p < 0.05). The EGF group showed markedly higher re-epithelialization scores than did the seton alone (S) and tarantula venom (T) groups. Granulation tissue was predominantly absent or immature in EGF compared to the mature or overly fibrotic profiles in the S and T groups. Inflammatory cell infiltration was significantly lower in EGF, whereas T demonstrated increased inflammation and highest Caspase-3 activity (74%). EGF maintained a minimal apoptotic response (~ 8.6% Caspase-3). EGF administration promoted favorable wound healing parameters, including enhanced re-epithelialization, reduced inflammatory infiltration, and minimal apoptotic injury in a rat perianal fistula model. Tarantula venom contributed to greater tissue damage, and seton placement alone achieved moderate outcomes. These findings suggest that EGF shows promise as an adjunctive treatment for perianal fistulas. However, its translational potential requires further investigation in clinical practice.
Indexed as
Identifiers
41272355What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.